Autolus Therapeutics (AUTL) Return on Capital Employed (2018 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Return on Capital Employed of 49.01% for Q4 2025, down 1657.0% year-on-year from 3.15% in Q4 2024, and down 8.84% on a QoQ basis from 45.03% in Q3 2025.
Autolus Therapeutics (AUTL) Return on Capital Employed (2018 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Return on Capital Employed for 7 consecutive years, with 49.01% the latest figure, recorded in Q4 2025.
- Quarterly Return on Capital Employed fell 1657.0% year-over-year to 49.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 49.01% (down 1657.0% YoY) and the FY2025 annual result came in at 44.17%, up 241.0% from the prior year.
- Return on Capital Employed eased to 49.01% in Q4 2025 per AUTL's latest filing, from 45.03% in the prior quarter.
- Over the last five years, Return on Capital Employed for AUTL reached as high as 23.17% in Q2 2024 and fell as low as 59.22% in Q3 2021.
- A 5-year average of 41.3% and a median of 39.6% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed slumped 4557 bps — and 2022, when it jumped 1956 bps.
- Year by year, Return on Capital Employed stood at 43.73% in 2021, then rose by 14 bps to 37.57% in 2022, then tumbled by 38 bps to 51.94% in 2023, then jumped by 38 bps to 32.43% in 2024, then plunged by 51 bps to 49.01% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 49.01%, 45.03%, and 40.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -49.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.01% |
| Sep 30, 2025 | -45.03% |
| Jun 30, 2025 | -40.60% |
| Mar 31, 2025 | -38.39% |
| Dec 31, 2024 | -32.43% |
| Sep 30, 2024 | -27.77% |
| Jun 30, 2024 | -23.17% |
| Mar 31, 2024 | -30.17% |
| Dec 31, 2023 | -51.94% |
| Sep 30, 2023 | -35.31% |
| Jun 30, 2023 | -31.98% |
| Mar 31, 2023 | -29.21% |
| Dec 31, 2022 | -37.57% |
| Sep 30, 2022 | -54.26% |
| Jun 30, 2022 | -45.71% |
| Mar 31, 2022 | -38.59% |
| Dec 31, 2021 | -43.73% |
| Sep 30, 2021 | -59.22% |
| Jun 30, 2021 | -53.73% |
| Mar 31, 2021 | -58.15% |